The cause of this difference was not determined.Ī mother took amphetamine 35 mg daily for narcolepsy during pregnancy and postpartum. In a retrospective Australian study, mothers who used intravenous amphetamines during pregnancy were less likely to be breastfeeding their newborn infants at discharge than mothers who abused other drugs (27% vs 42%). The maternal prolactin level in a mother with established lactation may not affect her ability to breastfeed. The authors also quoted data from another study showing that a 20 mg oral dose of dextroamphetamine produced a sustained suppression of serum prolactin by 40% in postpartum women. No assessment of milk production was presented. The 15 mg dose significantly decreased serum prolactin by 30 to 37% at times after the infusion. The 7.5 mg dose reduced serum prolactin by 25 to 32% compared to control, but the difference was not statistically significant. Eight received dextroamphetamine 7.5 mg intravenously, 6 received 15 mg intravenously and 6 who served as controls received intravenous saline. In 2 papers by the same authors, 20 women with normal physiologic hyperprolactinemia were studied on days 2 or 3 postpartum. These values represented 15%, 7% and 5% of simultaneous maternal serum concentrations. Infant serum concentrations at these times were 3.1, 2 and 1.4 mcg/L, respectively. Infant blood samples were taken just before the mother's morning amphetamine dose at 2, 5 and 9 weeks postpartum. The infant of a mother who was taking amphetamine 35 mg daily for narcolepsy during pregnancy and postpartum was exclusively breastfed for 6 months. The infant's urinary excretion of amphetamine ranged from 0.1 to 0.3% of the mother's urinary excretion. Amphetamine was measured in a 12-hour urine collection in a breastfed infant whose mother was taking racemic amphetamine 5 mg 4 times daily. Over the weekend Gustafson who is the developer of the app that prevents Macs from going into sleep mode received a call from the company informing him that the app will remain. The company is facing growing scrutiny regarding the consistency of its policies governing apps. These values represent a weight-adjusted dosage of 1.9% to 2.1% of the maternal dosage and an absolute infant dosage of 11.1 to 12.4 mcg/kg daily. Apple reverses decision to ban Amphetamine app. Breastmilk levels of amphetamine were 74, 82 and 82 mcg/L, respectively. Breastmilk samples were taken just before her morning dose at 2, 5 and 9 weeks postpartum. Milk levels were 118 and 138 mcg/L before the 2 pm doses on days 10 and 42, respectively.Ī woman took 35 mg of amphetamine daily for narcolepsy and exclusively breastfed her infant for 6 months.
#DEVELOPER AMPHETAMINE MACGUSTAFSONGITHUB MAC#
The proposed violation is even more peculiar given that Apple has previously spotlighted Amphetamine in a Mac App Store editorial dating back to the days of macOS Catalina. Trough milk levels of 55 and 68 mcg/L were found before the 10 am dose on days 10 and 42 postpartum, respectively. Originally released in 2014, Amphetamine has remained a widely used utility for nearly 6 years garnering a 4.8 out of 5-star rating from 1.4k satisfied users.
A nursing woman was taking racemic amphetamine 5 mg orally 4 times daily at 10 am, noon, 2 pm and 4 pm for narcolepsy. Thank you to all for sharing this story and helping to keep Amphetamine in the App Store.Īs such, it seems that Amphetamine will live on in the App Store with its current branding, which also includes a pill icon, as before.Maternal Levels. On that call, an Apple representative stated that Apple now recognizes that the word "amphetamine" and the pill icon are being used "metaphorically", and in a "medical sense." On January 2nd, 2021, I received a call from Apple to discuss the results of my appeal. Gustafson has stated that an Apple representative contacted him and informed him of the company's decision: It appears that the Cupertino tech giant has finally been convinced by Gustafson's argument as well the developer's tweet and petition gaining traction in the past couple of days, as it has decided to reverse its decision. Gustafson also filed an appeal to Apple, and stated that if the company does not agree, he would rebrand his app and work to raise awareness regarding Apple's actions. He went on to say that Amphetamine's branding is core to its identity, and the app was even featured by Apple itself a while ago.
Gustafson also highlighted examples of other apps actually promoting drugs in the App Store without any concerns raised by Apple. Gustafson argued that the app does not promote drugs in any way, and the drug of that name is actually legally prescribed to adults with narcolepsy and children for ADHD.
0 kommentar(er)
